Australasian Journal of Dermatology最新文献

{"title":"Dissecting cellulitis of the scalp in a paediatric male.","authors":"Meryl Thomas, Valerie Yii, Rodney Sinclair","doi":"10.1111/ajd.14342","DOIUrl":"https://doi.org/10.1111/ajd.14342","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug eruption and cutaneous metastasis in a patient with ALK-negative anaplastic large T-cell lymphoma after tislelizumab.","authors":"Ting Su, Xingbao Luan, Yan Lu, Yang Xu","doi":"10.1111/ajd.14337","DOIUrl":"https://doi.org/10.1111/ajd.14337","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study","authors":"Miguel Mansilla-Polo MD,&nbsp;Martí Pons-Benavent MD,&nbsp;Pablo Fernández-Crehuet MD, PhD,&nbsp;Eva Vilarrasa MD, PhD,&nbsp;Cristina Albanell-Fernández MD,&nbsp;Enrico Morales-Tedone MD,&nbsp;Francisca Rausell-Félix MD,&nbsp;Rebeca Alcalá-García,&nbsp;María Matellanes-Palacios MD,&nbsp;Gemma Martín-Ezquerra MD, PhD,&nbsp;Fernando Alfageme MD, PhD,&nbsp;Cristina Ciudad-Blanco MD, PhD,&nbsp;María Teresa López-Villaescusa MD,&nbsp;Patricia Garbayo-Salmons MD,&nbsp;Antonio Martorell MD, PhD,&nbsp;Begoña Escutia-Muñoz MD, PhD,&nbsp;Fernando Navarro-Blanco MD,&nbsp;Daniel Martín-Torregrosa MD,&nbsp;Carlos Cuenca-Barrales MD, PhD,&nbsp;Alejandro Molina-Leyva MD, PhD,&nbsp;Rafael Botella-Estrada MD, PhD","doi":"10.1111/ajd.14339","DOIUrl":"10.1111/ajd.14339","url":null,"abstract":"<p>In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (<i>p</i> &lt; 0.001), HS-PGA from 5.1 to 3.2 (<i>p</i> &lt; 0.001), VAS pain from 8.3 to 4.7 (<i>p</i> &lt; 0.001) and DLQI from 21.6 to 12.6 (<i>p</i> &lt; 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"e198-e202"},"PeriodicalIF":2.2,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermoscopic features of the normal vermilion in skin of colour","authors":"Biswanath Behera MD, DNB,&nbsp;Sonika Garg MD,&nbsp;Vishal Thakur MD,&nbsp;Shreya K. Gowda MD,&nbsp;Priyanka Sangwan MD","doi":"10.1111/ajd.14336","DOIUrl":"10.1111/ajd.14336","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"593-595"},"PeriodicalIF":2.2,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK inhibitors in refractory dermatomyositis: A case series","authors":"L. Corbella-Bagot MD,&nbsp;X. Bosch-Amate MD,&nbsp;E. Gimeno-Ribes MD,&nbsp;J. Gil-Lianes MD,&nbsp;P. Giavedoni MD,&nbsp;J. C. Milisenda MD,&nbsp;S. Prieto-González MD,&nbsp;R. Hurtado García,&nbsp;J. M. Mascaró Jr MD","doi":"10.1111/ajd.14335","DOIUrl":"10.1111/ajd.14335","url":null,"abstract":"<p>This retrospective cohort study assessed the efficacy and safety of Janus kinase (JAK) inhibitors, tofacitinib and baricitinib, in 14 patients with refractory dermatomyositis (DM), a multisystemic autoimmune disorder with limited therapeutic options. Results demonstrated a significant median decrease of 21 points and a 76% reduction in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, along with a complete resolution of muscular symptoms in 64% of the patients. JAK inhibitors were effective in managing refractory DM across various subtypes with mild and manageable adverse events.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"588-592"},"PeriodicalIF":2.2,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14335","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to the introduction of novel advanced targeted treatments for Australian dermatology patients: Are skin diseases symptomatic of a systemic healthcare problem?","authors":"Patrick David Mahar MBBS (Hons), LLB (Hons), MBA, MDerm, GDLP, PhD, DMedSc, FAICD, FACLM, FACD,&nbsp;Anna Crothers BCom, MHEcon,&nbsp;Peter Foley MBBS, BMedSc, MD, FACD,&nbsp;Joseph Thomas BA (Hons), PhD","doi":"10.1111/ajd.14333","DOIUrl":"10.1111/ajd.14333","url":null,"abstract":"<p>The aim of this article is to provide education to clinicians about certain barriers restricting the use of advanced targeted treatments in Australian health care. For illustrative purposes, the article focuses on dermatological conditions, but the content is relevant to all specialties that treat inflammatory and chronic diseases. Barriers to care discussed result in a lower than necessary standard of care for patients in Australia despite important advancements in medicine.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 6","pages":"e164-e167"},"PeriodicalIF":2.2,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vismodegib in Gorlin-Goltz syndrome: A systematic review","authors":"Ana Gusmão Palmeiro MD,&nbsp;Mélissa Carvalho MD,&nbsp;Cristina Gonçalves Castro MD,&nbsp;Bernardo Pimentel MD,&nbsp;Goreti Catorze MD","doi":"10.1111/ajd.14326","DOIUrl":"10.1111/ajd.14326","url":null,"abstract":"<p>Treatment with Hedgehog Inhibitors in Gorlin-Goltz syndrome (GGS) yields favourable objective clinical responses, yet secondary resistance and class-related toxicity restrict treatment duration. This study aims to review current data on GGS patients undergoing vismodegib therapy, focusing on treatment duration, clinical outcomes and schedule modifications. A systematic search of the PubMed database was conducted for English articles from 1993 to 2023, identifying 31 papers suitable for inclusion. A total of 351 patients, with a mean age of 52 years, were analysed. The average treatment duration was 9.3 months for patients who discontinued treatment, and 25.1 months for those who continued vismodegib at the time this study was published. Vismodegib achieved a complete response rate of 44%. Treatment interruption predominantly occurred due to side effects (69.1%) and secondary resistance (9.1%). The use of alternative regimens, although not compromising efficacy, may enhance treatment compliance. Further investigations are warranted to ascertain the optimal treatment regimen and timeline for GGS patients. Schedule modifications offer promise in ameliorating side effects and facilitating long-term treatment.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 6","pages":"e123-e133"},"PeriodicalIF":2.2,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141309929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient demographic characteristics and risk factors associated with sun protection behaviours in specialist melanoma clinics","authors":"Juliet Smith,&nbsp;David Espinoza,&nbsp;Amelia K. Smit,&nbsp;Bruna Gallo,&nbsp;Andrea L. Smith,&nbsp;Serigne N. Lo,&nbsp;Pascale Guitera,&nbsp;Linda K. Martin,&nbsp;Anne E. Cust","doi":"10.1111/ajd.14314","DOIUrl":"10.1111/ajd.14314","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We investigated the association between sun protection behaviours and demographic and melanoma risk characteristics of patients attending Australian melanoma specialist clinics. This may assist in targeting and tailoring melanoma prevention patient education for people at high-risk and specific population subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional analysis of questionnaire data collected from participants attending the dermatology clinics at two major melanoma centres in Sydney, Australia between February 2021 and September 2023. The primary outcome was Sun Protection Habits (SPH) index (a summary score measured as habitual past month use of sunscreen, hats, sunglasses, a shirt with sleeves that covers the shoulders, limiting midday sun exposure and seeking shade, using a Likert scale). The primary analysis considered the SPH index and its component items scored as continuous.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data from 883 people were analysed. Factors associated with less frequent sun protection behaviours overall included male gender, no personal history of melanoma, lower perceived risk, lower calculated 10-year risk of developing melanoma, and no private health insurance. People aged &gt;61 years reported lower use of sunscreen but higher use of hats and sleeved-shirts compared with people in the younger age group. There was no difference in overall sun protection behaviours according to family history of melanoma, country of birth or by lifetime melanoma risk among people without a personal history of melanoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings highlight the potential for targeting high-risk individuals with less frequent use of sun protection for patient education, public health messaging and ultimately improving sun protection behaviours.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 6","pages":"e156-e163"},"PeriodicalIF":2.2,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14314","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141282836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teledermatology in Australian public hospital emergency departments: A review","authors":"Danica Xie MD,&nbsp;John Sullivan FACD","doi":"10.1111/ajd.14327","DOIUrl":"10.1111/ajd.14327","url":null,"abstract":"&lt;p&gt;Dermatological complaints account for around one in ten emergency department (ED) presentations.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; In Australia, teledermatology in the ED is one strategy to increase access to dermatologic advice, especially in rural and remote communities where barriers such as travel time or lack of dermatology on-call cover, prevent timely communication and dermatological care.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;Diagnostic accuracy with in-person dermatology for asynchronous store-and-forward (SAF) teledermatology and real-time (RT) videoconferencing systems is 71–98%, while mobile phones as a platform for hybrid teledermatology reveal potential value in the early diagnosis of skin cancer.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;However, there is currently limited teledermatology implemented in the emergency department, despite having already been successfully trialled.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt; We reviewed the literature to identify the current benefits and limitations of teledermatology use in the hospital ED and highlight how this technology is best considered complementary to in-person dermatology.&lt;/p&gt;&lt;p&gt;Our literature search returned four eligible studies (&lt;i&gt;n&lt;/i&gt; = 660 patients) which were all based in the Australian healthcare system (Table 1).&lt;/p&gt;&lt;p&gt;The most common diagnoses were dermatitis/eczema, infection, and drug eruption (Table 2). Three of four studies conducted store-and-forward technology&lt;span&gt;&lt;sup&gt;2, 3, 7&lt;/sup&gt;&lt;/span&gt; while one study analysed RT teledermatology.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; The response rate within 3 h for dermatology advice ranged from 56% to 94%.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The benefits and limitations of teledermatology in the ED have been summarised below.&lt;span&gt;&lt;sup&gt;2, 3, 5, 7&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;This review reveals the value of ED teledermatology, with 50% of referrals being converted to non-urgent outpatient review, reducing the need for costly hospital admissions.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; In France, an RT teledermatology study of four ED's (&lt;i&gt;n&lt;/i&gt; = 111) revealed that ED physicians recommended admission more frequently (8.2% vs. 7.2%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), while dermatologists chose to discharge patients more often (46.8% vs. 39.1%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001).&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;Muir and colleagues&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; reported up to 98% diagnostic concordance using SAF technology in ED. Furthermore, the management concordance between the teledermatologists and in-person dermatologists were complete agreement in 96% of cases (&lt;i&gt;n&lt;/i&gt; = 48).&lt;/p&gt;&lt;p&gt;More than 80% of images in this review were sent with adequate resolution. Computer workstations on wheels (WOW) are mobile nodes of a hospital's electronic medical record and with high-definition cameras, WOW's could be a solution to managing dermatological conditions in contexts where specialists are scarce.&lt;/p&gt;&lt;p&gt;While many SAF studies used an internal teledermatology email to receive teledermatolo","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 6","pages":"535-537"},"PeriodicalIF":2.2,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14327","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of case–control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis","authors":"Thomas Jonathan Stewart BBioMedSci, MBBS, MMed, MS, FRACGP, FACD,&nbsp;Joshua Farrell BA, MBBS, MMed,&nbsp;John Walter Frew MBBS, MMed, MS, PhD, FACD","doi":"10.1111/ajd.14329","DOIUrl":"10.1111/ajd.14329","url":null,"abstract":"<p>Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions characterised by keratinocyte apoptosis, necroptosis and epidermal detachment. Several cytokines and cytotoxic proteins have been shown to be elevated in the blood and skin of SJS/TEN sufferers and biologics such as intravenous immune globulin and tumour necrosis factor (TNF)-alpha inhibitors have demonstrated good therapeutic potential. The exact pathogenic model of SJS/TEN however remains elusive. This systematic review aimed to evaluate the case–control studies of cytokines and cytotoxic proteins in the blister fluid and skin of adults with Stevens Johnson syndrome and/or toxic epidermal necrolysis. This review was registered with INPLASY and conducted in accordance with the PRISMA reporting guidelines. Potential bias was assessed using the NIH criteria. Eleven articles describing results from 96 cases and 170 controls were included. Fas, Fas ligand, Interleukin (IL)-8 and B-cell lymphoma (Bcl)-2 were elevated in SJS/TEN blister fluid and skin tissue, compared with healthy controls. IL-2, IL-6, TNF-alpha, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon-gamma and matrix metalloproteinase-2 were elevated in SJS/TEN blister fluid compared with fluid sampled from lesional controls. Granulysin, IL-33, TGF-beta-1 and IL-13 were elevated in SJS/TEN skin tissue compared with lesional lichen planus tissue, as was IL-13, IFN-gamma, IL-2 and IL-5, when compared with erythema multiforme tissue. A wide array of cytokines and cytotoxic proteins are present at higher concentrations in the blister fluid and skin tissue of SJS/TEN patients compared with healthy and lesional controls. Our findings suggest that these proteins may be pathogenic, as well as possibly markers for diagnosis, disease severity and course. They may also prove to be useful therapeutic targets. More research is needed.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 6","pages":"491-504"},"PeriodicalIF":2.2,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}